Assuming outcomes is required, the following results were found.

  • Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years

    Serum neurofilament light chain level was associated with brain fraction loss, whereas this was less the case for clinical outcomes such as relapses or EDSS worsening. Meaning The association of serum neurofilament light chain level with changes in...

    https://mschristian.org/index.php/blog/association-between-serum-neurofilament-light-chain-levels-and-long-term-disease-course-among-patients-with-multiple-sclerosis-followed-up-for-12-years
  • Sanofi and Happify Health solidify collaboration around prescription DTx designed to address mental health in people with MS

    evidence-based mental health digital therapeutics, to develop and study an app to help manage and improve psychological outcomes in people with MS. Digital therapeutics (DTx) deliver to patients evidence-based therapeutic interventions to patients that...

    https://mschristian.org/index.php/blog/sanofi-and-happify-health-solidify-collaboration-around-prescription-dtx-designed-to-address-mental-health-in-people-with-ms
  • Study shows importance of personal social networks on neurological outcomes

    "We find that there's a strong relationship between the health habits of people in a patient's social network and outcomes that are of interest to physicians who specialize in multiple sclerosis. This relationship must not be ignored when considering an...

    https://mschristian.org/index.php/blog/study-shows-importance-of-personal-social-networks-on-neurological-outcomes
  • Alcohol Consumption Linked to Lower MS Disability

    Sclerosis (CLIMB) study. Drinking habits were also assessed, and influence of alcohol or wine consumption on clinical outcomes was assessed using regression models for relapse rate in the past year, and concurrent EDSS and MSSS outcomes. Associations...

    https://mschristian.org/index.php/blog/alcohol-consumption-linked-to-lower-ms-disability
  • Capsule Technologies Launches Next Generation Clinical Computing Hub - P&T Community

    the evolving challenges providers face in managing complex device integration at the point of care and ensure quality outcomes for their patients," said Hemant Goel, CEO of Capsule Technologies. "Our clients are looking for more than just basic medical...

    https://mschristian.org/index.php/blog/capsule-technologies-launches-next-generation-clinical-computing-hub-p-t-community
  • Johns Hopkins researchers identify new way to lower blood pressure in obese patients

    mice, the researchers reported recently in the journal Circulation Research. Obesity leads to a lot of bad cardiovascular outcomes, and a significant portion of those are related to poorly controlled blood pressure. We've identified what may be a new...

    https://mschristian.org/index.php/blog/johns-hopkins-researchers-identify-new-way-to-lower-blood-pressure-in-obese-patients
  • #ECTRIMS2019 – Tysabri During Pregnancy and After Delivery Seems Safe, Reduces Relapse Risk, Study Finds

    then compared the annualized relapse rate (ARR) during pregnancy, and one year after delivery, as well as newborn outcomes, across groups. During pregnancy, there was a significantly higher relapse rate in the women with “wash-out” pregnancies — those...

    https://mschristian.org/index.php/blog/ectrims2019-tysabri-during-pregnancy-and-after-delivery-seems-safe-reduces-relapse-risk-study-finds
  • Genentech to Present Pivotal Data for Satralizumab in Neuromyelitis Optica Spectrum Disorder and Six-year Ocrevus (Ocrelizumab) Data in Multiple Sclerosis at ECTRIMS

    that advance understanding of neurofilament light chain (NfL) levels as a potential biomarker for predicting disability outcomes. Additionally, longer-term data of more than six years to be presented continue to show consistent safety and efficacy...

    https://mschristian.org/index.php/blog/genentech-to-present-pivotal-data-for-satralizumab-in-neuromyelitis-optica-spectrum-disorder-and-six-year-ocrevus-ocrelizumab-data-in-multiple-sclerosis-at-ectrims
  • Prescription digital therapeutics: reimagining disease treatment - STAT

    solutions (such as face-to-face cognitive behavioral therapy sessions) and can collect and quantify information about outcomes in real-world settings. By leveraging both of these features, developers can demonstrate to managed care providers the value...

    https://mschristian.org/index.php/blog/prescription-digital-therapeutics-reimagining-disease-treatment-stat
  • CareCentrix Releases New Series of #CareTalk Podcasts and Videos Shot Live at HLTH - P&T Community

    patients to identify rare genetic conditions, discussed how this technology can support providers, while improving patient outcomes, by enabling earlier and more accurate diagnostics. Andy Slavitt, Founder and Board Chair of United States of Care, and...

    https://mschristian.org/index.php/blog/carecentrix-releases-new-series-of-caretalk-podcasts-and-videos-shot-live-at-hlth-p-t-community
  • First clues to the causes of multiple sclerosis

    with the viral pathogen developed an inflammatory brain disease reminiscent to Multiple Sclerosis." Based on these outcomes, the scientists analysed how the expression of the genes in the CD8+ T cells varied according to the pathogen used to activate...

    https://mschristian.org/index.php/blog/first-clues-to-the-causes-of-multiple-sclerosis
  • Does sunlight change our gut microbiome?

    sunlight affect our gut microbiomes? There is plenty of evidence that links vitamin D, the sunshine vitamin, to health outcomes. Living at higher latitudes, which means less exposure to UV light and a greater chance of being vitamin D deficient, carries...

    https://mschristian.org/index.php/blog/does-sunlight-change-our-gut-microbiome
  • Research Project 3TR To Use Breath Biopsy, Improve Immune-mediated Disease Management - Technology Networks

    biomarkers, on breath or other sample types that can be deployed to detect disease earlier and to drive improved patient outcomes. 3TR’s ground-breaking approach to addressing this problem through integrated cross-disease analysis, led by leading...

    https://mschristian.org/index.php/blog/research-project-3tr-to-use-breath-biopsy-improve-immune-mediated-disease-management-technology-networks
  • #ECTRIMS2019 - Are Injectables Inappropriate for Active Relapsing MS? - Multiple Sclerosis News Today

    (DMTs). DMTs used as second-line treatments, compared with first-line injectables, offer benefits in several clinical outcomes, namely annual relapse rates, disability progression, treatment resistance, and health-related quality of life. With more...

    https://mschristian.org/index.php/blog/ectrims2019-are-injectables-inappropriate-for-active-relapsing-ms-multiple-sclerosis-news-today
  • 'We're Just Out of Shape and Weak': What We Heard This Week

    survival." -- Clifton Callaway, MD, PhD, of the University of Pittsburgh, on findings that hypothermia improved neurologic outcomes for patients in a coma after cardiac arrest with nonshockable rhythm. "If the message to patients is, 'You need to quit...

    https://mschristian.org/index.php/blog/we-re-just-out-of-shape-and-weak-what-we-heard-this-week
  • Blood neurofilament light chain as a biomarker of MS disease activity and treatment response

    and interferon [IFN]-β-1a, TRANSFORMS) and 35 healthy controls and compared NfL levels with clinical and MRI-related outcomes. Results At baseline, NfL levels (pg/mL) were higher in patients than in healthy controls (30.5 and 27.0 vs 16.9, p = 0.0001)...

    https://mschristian.org/index.php/blog/blood-neurofilament-light-chain-as-a-biomarker-of-ms-disease-activity-and-treatment-response
  • Novartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-head Phase III multiple sclerosis studies

    authorities by end of 2019. “It is clear that early initiation of highly effective treatment for MS improves long-term outcomes, and there is a high need for potent, safe, and convenient therapy that can be used to treat MS from the start,” said...

    https://mschristian.org/index.php/blog/novartis-ofatumumab-demonstrates-superiority-versus-aubagio-in-two-head-to-head-phase-iii-multiple-sclerosis-studies
  • NIH trial aims to improve drug discovery for ischemic stroke

    as randomization and blinding) more similar to the ones used in clinical trials. The aim is to improve clinical trial outcomes, as many drugs fail during human testing. Seven laboratories will collaborate to apply the robust practices when testing the...

    https://mschristian.org/index.php/blog/nih-trial-aims-to-improve-drug-discovery-for-ischemic-stroke
  • Assessment and Measurement of Spasticity in MS: State of the Evidence.

    to be developed as our understanding of spasticity in MS grows. KEYWORDS: Assessment; Measurement; Multiple sclerosis; Outcomes; Spasticity Source This Article is Provided by: #MSViewsandNews...

    https://mschristian.org/index.php/blog/assessment-and-measurement-of-spasticity-in-ms-state-of-the-evidence
  • Fooling nerve cells into acting normal

    Discovery could inform future studies related to spinal cord injuries, multiple sclerosis and epilepsy Date:Source:University of Missouri-ColumbiaSummary:Scientists have discovered that a neuron's own electrical signal, or voltage, can indicate whether...

    https://mschristian.org/index.php/blog/fooling-nerve-cells-into-acting-normal

Results 1 - 20 of 27
 
 

Follow Us on Twitter

Follow Us On Twitter - Image